How have NBSE shares performed in 2024?

NeuBase Therapeutics' stock was trading at $0.7401 on January 1st, 2024. Since then, NBSE shares have decreased by 44.5% and is now trading at $0.4110. View the best growth stocks for 2024 here .

Are investors shorting NeuBase Therapeutics?

NeuBase Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 149,100 shares, an increase of 85.2% from the March 15th total of 80,500 shares. Based on an average daily volume of 233,400 shares, the short-interest ratio is presently 0.6 days. Approximately 4.9% of the company's stock are short sold. View NeuBase Therapeutics' Short Interest .

When is NeuBase Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our NBSE earnings forecast .

How were NeuBase Therapeutics' earnings last quarter?

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) released its quarterly earnings data on Thursday, December, 23rd. The company reported ($4.20) EPS for the quarter, beating analysts' consensus estimates of ($4.60) by $0.40.

When did NeuBase Therapeutics' stock split?

NeuBase Therapeutics's stock reverse split on the morning of Thursday, June 15th 2023. The 1-20 reverse split was announced on Thursday, June 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of NeuBase Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuBase Therapeutics investors own include Sorrento Therapeutics (SRNE) , Dynavax Technologies (DVAX) , Ovid Therapeutics (OVID) , Advanced Micro Devices (AMD) , Enterprise Products Partners (EPD) , Flexion Therapeutics (FLXN) , Pfizer (PFE) , VBI Vaccines (VBIV) , AbbVie (ABBV) and Aravive (ARAV) .

How do I buy shares of NeuBase Therapeutics?

Shares of NBSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NBSE

NeuBase Therapeutics (NBSE) Stock Price, News & Analysis

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)

Free NBSE Stock Alerts

$0.41

-0.01 (-2.12%)

(As of 11:14 AM ET)

Compare

Today's Range: $0.41
▼
$0.43
50-Day Range: $0.40
▼
$1.07
52-Week Range: $0.39
▼
$5.40

Volume: 28,416 shs
Average Volume: 211,134 shs
Market Capitalization: $1.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get NeuBase Therapeutics alerts:

Ad TradeSmith

A.I. Pioneer Issues Urgent Warning to Americans

According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”

Click here to learn more while there’s still time.

About NeuBase Therapeutics Stock (NASDAQ:NBSE)

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

NBSE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NBSE Stock News Headlines

April 6, 2024 | finanznachrichten.de

NeuBase Therapeutics, Inc.: NeuBase Therapeutics Announces Receipt of Notice from Nasdaq

April 5, 2024 | globenewswire.com

NeuBase Therapeutics Announces Receipt of Notice from Nasdaq

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”

March 27, 2024 | msn.com

Why Neubase Therapeutics (NBSE) Shares Are Nosediving

March 26, 2024 | msn.com

NeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics among healthcare movers

March 26, 2024 | investorplace.com

Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?

March 25, 2024 | bizjournals.com

NeuBase Therapeutics sets shareholder meeting on dissolution plan

February 26, 2024 | edition.cnn.com

NeuBase Therapeutics Inc

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”

February 20, 2024 | finance.yahoo.com

NeuBase Therapeutics, Inc. (NBSE)

January 20, 2024 | ca.finance.yahoo.com

NeuBase Therapeutics Inc (O7P.BE)

December 22, 2023 | bizjournals.com

CMU halts licensing agreement with NeuBase Therapeutics

November 27, 2023 | finance.yahoo.com

Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance

November 6, 2023 | morningstar.com

NeuBase Therapeutics Inc NBSE

October 6, 2023 | finance.yahoo.com

NeuBase Therapeutics, Inc. (NBSE.MX)

September 12, 2023 | benzinga.com

Massive Insider Trade At NeuBase Therapeutics

September 12, 2023 | msn.com

NeuBase falls after largest shareholder disposes of part stake

September 8, 2023 | finance.yahoo.com

NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder

September 6, 2023 | markets.businessinsider.com

Why Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?

August 16, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: NeuBase Therapeutics (NBSE) and Centessa Pharmaceuticals (CNTA)

August 6, 2023 | fool.com

NeuBase Therapeutics (NASDAQ: NBSE)

August 3, 2023 | finance.yahoo.com

NeuBase Therapeutics to Explore Strategic Alternatives

August 1, 2023 | bizjournals.com

Pittsburgh biotech firm amends stock incentive plan

June 30, 2023 | finance.yahoo.com

NeuBase Announces Closing of $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules

June 29, 2023 | finance.yahoo.com

NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to Redosing

June 28, 2023 | finance.yahoo.com

NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules

June 14, 2023 | finanznachrichten.de

NeuBase Therapeutics, Inc.: NeuBase Announces 1-for-20 Reverse Stock Split

See More Headlines

Receive NBSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 12/23/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NBSE
CUSIP: N/A
CIK: 1173281
Web: www.neubasetherapeutics.com
Phone: (164) 645-1790
Fax: N/A
Employees: 37
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($7.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,370,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -99.74%
Return on Assets: -60.13%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.87
Quick Ratio: 2.87

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $11.04 per share
Price / Book: 0.04

Miscellaneous

Outstanding Shares: 3,752,000
Free Float: 3,230,000
Market Cap: $1.58 million
Optionable: Not Optionable
Beta: 0.83

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Todd P. Branning (Age 53)
Interim CEO, CFO & Secretary
Comp: $427.44k
Dr. Dietrich A. Stephan Ph.D. (Age 54)
Founder, President & Director
Comp: $836.58k

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

NBSE Stock Analysis - Frequently Asked Questions

How have NBSE shares performed in 2024?: NeuBase Therapeutics' stock was trading at $0.7401 on January 1st, 2024. Since then, NBSE shares have decreased by 44.5% and is now trading at $0.4110.
View the best growth stocks for 2024 here.
Are investors shorting NeuBase Therapeutics?: NeuBase Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 149,100 shares, an increase of 85.2% from the March 15th total of 80,500 shares. Based on an average daily volume of 233,400 shares, the short-interest ratio is presently 0.6 days. Approximately 4.9% of the company's stock are short sold.
View NeuBase Therapeutics' Short Interest.
When is NeuBase Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our NBSE earnings forecast.
How were NeuBase Therapeutics' earnings last quarter?: NeuBase Therapeutics, Inc. (NASDAQ:NBSE) released its quarterly earnings data on Thursday, December, 23rd. The company reported ($4.20) EPS for the quarter, beating analysts' consensus estimates of ($4.60) by $0.40.

When did NeuBase Therapeutics' stock split?: NeuBase Therapeutics's stock reverse split on the morning of Thursday, June 15th 2023. The 1-20 reverse split was announced on Thursday, June 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of NeuBase Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other NeuBase Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Flexion Therapeutics (FLXN), Pfizer (PFE), VBI Vaccines (VBIV), AbbVie (ABBV) and Aravive (ARAV).
How do I buy shares of NeuBase Therapeutics?: Shares of NBSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NBSE) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

NeuBase Therapeutics (NBSE) Stock Price, News & Analysis

About NeuBase Therapeutics Stock (NASDAQ:NBSE)

NBSE Stock Price History

NBSE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

NBSE Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info